External Quality Assessment for the Detection of Chlamydia trachomatis in Urine Using Molecular Techniques in Belgium
Table 4
The proficiency per detection methods.
#
Method
N1
Spls2
+3
−4
Ac5 (%)
Se6 (%)
Sp7 (%)
Swedish variant
B08-07
A09-07
B09-02
A10-03
B10-05
A11-04
B11-03
A12-01
Total
%
1
Nanogen Chlamydia tr. Q-PCR Alert
8
48
40
8
93.70
90.00
100.00
1/1
1/1
1/1
1/1
1/1
1/1
1/1
1/1
8/8
100.0
2
Roche Cobas TaqMan CT8
93
547
454
93
90.10
88.10
100.00
0/4
0/9
10/10
14/14
14/14
14/14
12/12
6/12
76/89
85.4
3
Abbott real time CT/NG
56
303
247
56
87.40
92.30
98.20
1/1
2/2
2/2
5/5
8/8
10/10
13/13
11/15
52/56
92.9
4
Abbott real time CT
17
103
86
17
83.50
80.20
100.00
2/2
1/2
2/2
2/2
2/2
2/2
2/2
1/2
14/16
87.5
5
Qiagen artus C. trachomatis Plus
48
297
249
48
81.80
78.30
100.00
5/5
7/7
6/6
6/6
5/5
5/5
5/5
3/4
42/43
97.7
6
BD Diagnostics BD ProbeTec ET
70
441
371
70
75.90
78.20
95.70
10/10
9/9
8/8
8/8
7/7
6/6
6/6
2/5
56/59
94.9
7
Roche Cobas Amplicor CT/NG
53
359
306
53
75.20
71.20
98.10
0/10
NA
4/8
0/4
0/2
0/2
0/1
NA
4/27
14.8
8
Roche Amplicor CT/NG
51
329
278
51
64.10
59.40
94.10
0/11
4/17
1/8
0/7
0/5
0/3
0/2
0/3
5/56
8.9
Total
396
2427
2031
396
80.2
78.8
98.0
22/47
24/47
36/48
39/50
42/49
41/46
39/41
26/42
257/354
72.6
46.8%
51.1%
75.0%
78.0%
85.7%
89.1%
95.1%
61.9%
72.6%
: The number of samples panels analyzed using this method. 2The number of analyzed samples. 3+: the number of positive samples analyzed. 4−: the number of negative samples analyzed. 5Ac: accuracy = percentage of correct results. 6Se: sensitivity percentage of correct results for positive samples. 7Sp: specificity = percentage of correct results for negative samples. 8Roche Cobas TaqMan CT (for 2008 and first survey of 2009) and Roche Cobas TaqMan CT v2.0 (since second survey of 2009). NA: not applicable.
